Optimal treatment of hypertension in African Americans

References

• Grimm RH Jr, Margolis KL, Papademetriou VV, et al. Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2001; 37(1): 19–27
   Google Scholar
• Sica DA, Douglas JG. The African American Study of Kidney Disease and Hypertension (AASK): new findings. J Clin Hypertens (Greenwich) 2001; 3(4): 244–51
   Google Scholar
• Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285(21): 2719–28
   PubMed Web of Science ®Google Scholar
• The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157(21): 2413–46
   PubMedGoogle Scholar
• 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 1999; 17(2): 151–83
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy D. Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 1999; 317(3): 168–75
   PubMed Web of Science ®Google Scholar
• US Renal Data System 2001 annual data report: atlas of end-stage renal disease in the United States. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
   Google Scholar
• Jamerson K, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med 1996; 101(3A): 22–32S
   Google Scholar
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub- study. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253–9
   PubMed Web of Science ®Google Scholar
• Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001; 345(12): 910–2
   Google Scholar
• Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96(8): 2751–3
   PubMed Web of Science ®Google Scholar
• Third report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Cholesterol Education Program. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute, 2001
   Google Scholar
• Prisant LM, Mensah GA. Use of beta-adrenergic receptor blockers in blacks. J Clin Pharmacol 1996; 36(10): 867–73
   Google Scholar
• Richardson AD, Piepho RW. Effect of race on hypertension and antihypertensive therapy. Int J Clin Pharmacol Ther 2000; 38(2): 75–9
   Google Scholar
• Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339(8): 489–97
   PubMed Web of Science ®Google Scholar
• Haywood LJ. Coronary heart disease mortality/morbidity and risk in blacks. I. Clinical manifestations and diagnostic criteria: the experience with the Beta Blocker Heart Attack Trial. Am Heart J 1984; 108(3 Pt 2): 787–93
   Google Scholar
• Turner ST, Schwartz GL, Chapman AB, et al. C825T polymorphism of the G protein ß3-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37(2 Pt 2): 739–43
   Google Scholar
• Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341 (19): 1447–57
   PubMed Web of Science ®Google Scholar
• Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997; 80(11): 1453–8
   PubMed Web of Science ®Google Scholar
• Weir MR, Gray JM, Paster R, et al. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995; 26(1): 124–30
   Google Scholar
• Flack JM, Mensah GA, Ferrario CM. Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage. Curr Med Res Opin 2000; 16(2): 66–79
   PubMed Web of Science ®Google Scholar
• Bakris G, White D. Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens 1997; 11(1): 35–8
   PubMedGoogle Scholar
• Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344(18): 1351–7
   PubMed Web of Science ®Google Scholar
• Rahman M, Douglas JG, Wright JT Jr. Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab Clin North Am 1997; 26(1): 125–44
   Google Scholar
• Fogari R, Corea L, Cardoni O, et al. Combined therapy with benazepril and amlodipine in the treatment of hypertension inadequately controlled by an ACE inhibitor alone. J Cardiovasc Pharmacol 1997; 30(4): 497–503
   Google Scholar
• Frishman WH, Ram CV, McMahon FG. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel- group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol 1995; 35(11): 1060–6
   PubMed Web of Science ®Google Scholar
• Gainer JV, Nadeau JH, Ryder D, et al. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 1996; 98(2): 283–7
   Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–60
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861–9
   PubMed Web of Science ®Google Scholar
• Parving H-H, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12): 870–8
   PubMed Web of Science ®Google Scholar
• McGill JB, Reilly PA. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 2001; 24(1): 66–72
   Google Scholar
• Flack JM, Saunders E, Gradman A, et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2001; 23(8): 1193–208
   PubMed Web of Science ®Google Scholar